Even though the activation of the Fas/FasL pathway was considered as a treatment for RA, data from in-vitro and in-vivo models have shown that Fas activation may stimulate inflammation rather than induce apoptosis (7-9). Here, FASLG is linked to rheumatoid arthritis.